Google
Trusted Resources: News & Events
Latest announcements and gatherings
Matthew Porteus awarded grant for sickle cell anemia work
The California Institute for Regenerative Medicine has awarded MATTHEW PORTEUS, associate professor of pediatrics, a grant of $5.2 million to lay the groundwork for a clinical trial of a possible treatment for sickle cell disease.
Porteus has shown that he can take human blood stem cells with the gene defect that causes sickle cell disease and use gene-editing tools to repair the faulty gene. He also showed that he could successfully transplant those repaired blood stem cells into mice.
“We are extremely excited that, with CIRM support, we may be able to use gene correction to treat this terrible disease,” Porteus said.
+myBinderRelated Content
-
Arterio-venous fistula for automated red blood cells exchange in patients with sickle cell disease: Complications an...Erythrocytapheresis (ER) can improve out...
-
Sickle Cell Disease: Pain ManagementPain is a long-lasting problem for peopl...
-
Stem cell gene-editing method may be breakthrough for sickle cell researchResearchers have cured mice with a genet...
-
What Should Teens Ask Their Doctors About Hydroxyureahttps://www.youtube.com/watch?v=VZn15uXQ...
-
Sickle Cell Disease Research Shows Progress in Preventing Related Complications and DeathStudies aim to limit pain crises, preven...
-
Emmaus, a leader in sickle cell disease treatment, signs agreement with McKesson to expand distribution network for ...Emmaus Life Sciences, Inc., anno...
-
Alabama Man Free of Sickle Cell After Gene Therapyhttps://www.youtube.com/watch?v=E9vYON8D...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.